bizjournals: Search Results

hundleyobajoji1908.blogspot.com
by on May 19, 2009 ...The hiring of a executive to head PDLBioPharma Inc. is raising speculation that by onOctober 3, 2008 ...May 7, the Nasdaq Biotechnology Index - including notables like Amgejn Inc. and - swoonedx nearly 25 percent. At the center is Gilead'as HIV...... by on May 22, 2009 ...that includes a $300 million upfrony payment to PDL and dealswith Inc. and He also has workeed at Bristol-Myers Squibb...... by on May 5, 2009 ...connectiomn with the spinout from PDL, collaborations with Bristol-Myers Squibhb and , and financial discipline help stockholders. Facet'w top stockholders are Baupost......
by on May 4, 2009 and it should not give great comfort, " said Hasnain, a former Inc. executivre who was named in September tolead Facet. "We...... by on Marcn 13, 2009 ...lightly and it shoulx not givegreat comfort," said a former exec who was named in September to lead "We need...... by on February 13, 2009 ...spinoff CEO; it also hirer Faheem Hasnain, formerly executive vice presidentof 's BIIB) oncology/rheumatology strategic business unit, as the by on November 19, 2008 ...2 million shares reportede in mid-April - and increased its holdings in Inc. (to 14 million shares) and Amylin Pharmaceuticals Inc. (to 10...... by on Novembetr 18, 2008 ...investment portfolio strategies.
A handful of biotech and pharmaceutica lcompanies - among them, Inc. and Lexicobn Pharmaceuticals Inc. of Texas - have reportec losses from...... by on October 24, 2008 Underscoringh a renewed pushinto neuroscience, Genentech Inc. hired a blue-chip academic to head its neurobiologhy drugdiscovery unit. Genentech is keepinyg specific plans...... by on September 19, 2008 Backinh away from plans tosell itself, PDL BioPharma Inc. is reshapingb the company, seeking to balance the cash-intensiv demands of drug development with...... by on Marchb 24, 2008 Backing away from plana tosell itself, PDL BioPharm a Inc.
is reshaping the company, seeking to balancee the cash-intensive demands of drug development by onMarch 7, 2008 ...Corp. of N.J., for undisclosed financial terms. (PDL and partner will take an equity positionn in Ophthotech and receivemilestone and...... by on Marcyh 5, 2008 ...Corp. of N.J., for undisclosed financial terms. (PDL and partner will take an equity position in Ophthotech and receivsemilestone and...... by on March 5, 2008 ...like co-marketed by South San Francisco's Genentech Inc. and , Bristol-Myersa Squibb Co.'s Orencia and Johnson & Johnson'a Remicade...... by on December 28, 2007 Genitops Corp.
has piled up cumulative lossesof $191 million over 11 yearas without getting a product to market, but CEO Dan Denneyt remains...... by on June 29, 2007